The company is planning a 2020 commercial launch of PNNL's SLIM IMS tech, which could significantly improve the sensitivity and throughput of mass spec assays.
Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
However, a shift within the field towards experiments comprising larger numbers of samples and conditions may give DIA an advantage in the future.
In a recent study, researchers combined genomic and proteomic data to identify mutations responsible for a pair of rare monogenic neutrophil diseases.
The study made use of a high-resolution mass spec approach developed by University of Minnesota scientists that allows for untargeted discovery of DNA adducts.
The company reported revenues of $553.6 million, up from $530.5 million in Q4 2017, and beating the average analyst estimate of $544.6 million.
The approach allows researchers to profile the protein complexes present in a sample in much the same way they have the individual peptides and proteins.
The researchers presented new reagents and software for de novo peptide sequencing, an emerging technology with potential in proteomics and biopharma.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
The resource provides a look at protein localization patterns across the proteome as well as responses to events like alternative splicing and drug perturbation.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
The team compiled these proteins in three panels that could help researchers better assess plasma sample quality in protein biomarker work.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
Researchers at the University of Copenhagen used mass spectrometry to analyze dental plaque from 21 individuals recovered from a medieval Danish gravesite.
Revenues in the third quarter grew to $466.6 million from $335.6 million in Q3 2017, beating the consensus Wall Street estimate of $451.7 million.
New work has looked at how common HLA peptide splicing is, which has significance for immunotherapy and infectious disease research.
The company reported $5.92 billion in revenues for the quarter, driven by growth across its four business segments.
Agena has an ongoing partnership with Guangzhou-based DaRui to develop MassArray-based diagnostics for cancer and inherited diseases for the Chinese market.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.